Earthworm has provided a £2.2m Series B investment to support Weedingtech as it expands its herbicide-free weed control technology internationally.
"We believe the investment from Earthworm recognises two key things. Firstly, the success Weedingtech has had to date supplying the market with a popular and essential alternative to traditional chemical herbicides. And secondly, the global high-growth potential that the herbicide-free sector holds as organisations increasingly look to reduce their reliance on traditional chemical herbicides. Weedingtech was founded on very similar values to Earthworm in that we wanted to develop and supply products that benefit the environment. It’s an exciting time to be in this sector and we are delighted to have a new investor who shares our vision and values."
The London-based simulation technology firm secured backing from Barclays, Graphene Ventures, and Gauss Ventures to drive talent acquisition and product growth.
"Simudyne technology is proven to help banks solve challenges such as understanding market contagion, stress testing and simulating market execution"
The financing round was led by RT Ventures and will support the US commercial roll-out of the company test.
"This Series B financing allows us to commercialize our lead product in patients with advanced lung cancer, following our positive reimbursement decision. We also have an exciting portfolio of future products that will be advanced in parallel to maximize the benefits of our industry-leading InVision Liquid Biopsy platform to patients. We are grateful to our existing investors for their continued support and are delighted to welcome RT Ventures to our already strong investor base. With these funds in place, we look forward to continuing our mission to transform the lives of cancer patients through the power of liquid biopsy."
